NanoViricides, Inc. (NYSE American: NNVC) announced that it has shipped NV-387 Oral Gummies to the Democratic Republic of Congo (DRC) in preparation for a Phase II clinical trial evaluating the drug as a treatment for MPox. The company stated that site preparations are being conducted by its contract research organization, Om Sai Clinical Research Pvt. Ltd., and local partners, with patient enrollment and dosing expected to begin following completion of staff training in the coming weeks.
The trial will assess the safety and effectiveness of NV-387 in patients with MPox caused by human monkeypox virus infection, primarily the more severe Clade I strain endemic to the DRC. NanoViricides noted that NV-387, a broad-spectrum antiviral candidate, has also been proposed for evaluation against Ebola virus infections. The shipment makes the drug locally available should it be utilized in response efforts. Successful clinical development of NV-387 could position the therapy as a potential treatment option for multiple viral diseases, including MPox and Ebola.
NV-387 is the company's lead drug candidate and is being developed as a treatment for RSV, COVID-19, Long COVID, Influenza, and other respiratory viral infections, as well as MPox/Smallpox and Measles. The company also has other advanced drug candidates, including NV-HHV-1 for Shingles. NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials.
The company's platform technology is based on the TheraCour® nanomedicine technology, which it licenses from TheraCour Pharma, Inc. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs targeting specific human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Dengue, Japanese Encephalitis, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses.
This development is significant as it marks a critical step in advancing a potential broad-spectrum antiviral therapy that could address multiple viral threats. The DRC has experienced severe MPox outbreaks, and the availability of a new treatment could have a substantial impact on public health in the region. Additionally, the potential for NV-387 to be used against Ebola underscores its versatility and importance in pandemic preparedness.
For more information, the full press release is available at https://ibn.fm/CTIZc. Latest news and updates on NanoViricides can be found at https://ibn.fm/NNVC.
